Medication ReconciliationNCT01226589
Pharmacist Discharge Medication Reconciliation Study
A study testing MRS in people with Medication Reconciliation, run by Alberta Health services at 1 site in Canada.
Trial summary
Adverse drug events can occur commonly due to medication errors during the transition of care in a health care facility. Medication reconciliation is the process of comparing medications and providing an accurate medication list as a resource for prescribers, which is currently only being done upon inpatient admission… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Medication Reconciliation
- What is being tested?
- MRS
- Type of treatment
- Surgery or procedure
- How many people
- 50 participants
- Where
- 1 siteCanada
- Study dates
- Oct 2007to Oct 2008
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Cancer inpatients under the care of Dr. Follett or Dr. Candler
- Cancer inpatients to be discharged from the CCI
- Patients >18 years of age
- Patients that are taking >1 medications or herbals total at home.
Who cannot join
- Cancer inpatients that are considered radioactive or in "hot rooms" (ie. Selectron patients or patients receiving radiation treatment for thyroid)
- Patients that do not remain in hospital >72 hours
- Patients without a home phone number or equivalent contact number.
- Language barrier (patients unable to speak or understand English).
- Patients that are readmitted and already included into the study.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Impact of Pharmacist Discharge Medication Reconciliation on Unintentional Medication Discrepancies From Inpatient Discharges at the Alberta Cancer Board Cross Cancer Institute
Adverse drug events can occur commonly due to medication errors during the transition of care in a health care facility. Medication reconciliation is the process of comparing medications and providing an accurate medication list as a resource for prescribers, which is currently only being done upon inpatient admission at the CCI. The purpose of this study is to see if pharmacist medication reconciliation at discharge reduces unintentional medication discrepancies for inpatient discharges.
- Conditions
- Medication Reconciliation
- Being tested
- MRS
- Keywords
- Cancer cancer, MRS, Treatment response, Histologically confirmed diagnosed Breast cancer., Patient is 18 years or older., Karnofsky performance score is equal to or greater than 70., No previously irradiated or recurrent breast., No contraindication to MRS/MRI.
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MRSProcedure or surgery
What is being measured
The primary outcome is the main question the study is designed to answer.
MRS Correlation with Treatment Response.
The percentage of patients with at least one unintentional medication discrepancy after discharge from the Cross Cancer Institute
Measured: up to 1 year
Secondary outcomes (2)
Correlation with Tumor Stage
The amount of medication discrepancies after discharge that has the potential to cause moderate harm to severe harm.
Measured: up to 1 year
The frequency of each type of unintentional medication discrepancies.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Oct 2010 (estimated)
- Study startOct 2007
- Study completionOct 2008
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Medication ReconciliationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Alberta Health services
- Sponsor type
- University, hospital or other
- Investigators
- Carole Chambers, BSc. Pharmacy, Principal investigator, AHS Cancer Control Alberta
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01226589
- Sponsor's protocol ID
- 23851
- Status last verified
- Apr 2011
- First submitted
- 21 Oct 2010
- Last updated
- 19 Apr 2011
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 19 Apr 2011. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Impact of Pharmacist Discharge Medication Reconciliation on Unintentional Medication Discrepancies From Inpatient Discharges at the Alberta Cancer Board Cross Cancer Institute
- ClinicalTrials.gov ID
- NCT01226589
- Acronym / sponsor ID
- 23851
- Conditions
- Medication Reconciliation
- Keywords
- Cancer cancer, MRS, Treatment response, Histologically confirmed diagnosed Breast cancer., Patient is 18 years or older., Karnofsky performance score is equal to or greater than 70., No previously irradiated or recurrent breast., No contraindication to MRS/MRI.
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Alberta Health servicesUniversity, hospital or other
- Study start
- Oct 2007
- Study completion
- Oct 2008 (actual)
- First posted
- 22 Oct 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Adverse drug events can occur commonly due to medication errors during the transition of care in a health care facility. Medication reconciliation is the process of comparing medications and providing an accurate medication list as a resource for prescribers, which is currently only being done upon inpatient admission at the CCI. The purpose of this study is to see if pharmacist medication reconciliation at discharge reduces unintentional medication discrepancies for inpatient discharges.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- None (open label)
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Cancer inpatients under the care of Dr. Follett or Dr. Candler
- Cancer inpatients to be discharged from the CCI
- Patients >18 years of age
- Patients that are taking >1 medications or herbals total at home.
Key exclusion criteria (5 listed)
- Cancer inpatients that are considered radioactive or in "hot rooms" (ie. Selectron patients or patients receiving radiation treatment for thyroid)
- Patients that do not remain in hospital >72 hours
- Patients without a home phone number or equivalent contact number.
- Language barrier (patients unable to speak or understand English).
- Patients that are readmitted and already included into the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MRS | Procedure or surgery | – |
Primary outcome
MRS Correlation with Treatment Response.
Time frame: up to 1 year
The percentage of patients with at least one unintentional medication discrepancy after discharge from the Cross Cancer Institute
2 secondary outcomes
Correlation with Tumor Stage
Time frame: up to 1 year
The frequency of each type of unintentional medication discrepancies.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Apr 2011.
Related trials for Medication Reconciliation
Not yet recruiting
A Study to Investigate Health Related Quality of Life With a Pharmacist Intervention Compared to Treatment as Usual in Participants With Severe Mental Illness and Substance Use Disorder Receiving Treatment From FACT Teams.
Severe Mental Illness, Substance Use Disorder (SUD)
Enrolling by invitation
Improving Medication Therapy Through a Digital Interdisciplinary Medicine Therapy Optimisation Model
Medication-related Problems, Self-reported Medication Adherence
Enrolling by invitation
Telehealth Education Leveraging Electronic Transitions Of Care for COPD Patients
COPD Exacerbation, Care Transitions
Not yet recruiting
Optimization of Medical Time in the Emergency Department: Impact of an AI-Based System on Prescription Entry
Drug-related Iatrogenesis, Emergency Department
Active, not recruiting
Appropriate Medication Use for Individuals With Intellectual Disabilities - A Matter of Life
Disabilities, Intellectual, Disability, Developmental
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Carole Chambers, BSc. Pharmacy principal investigator
AHS Cancer Control Alberta
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing MRS in people with Medication Reconciliation, run by Alberta Health services at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Apr 2011. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
MRS Correlation with Treatment Response. (time frame: up to 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Apr 2011.